Published in Clin Pharmacol Ther on April 16, 2008
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One (2010) 0.99
Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2). Pharmacogenet Genomics (2011) 0.80
The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. Oncotarget (2015) 0.80
Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI. PLoS One (2016) 0.77
Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples. Int J Cancer Res Mol Mech (2015) 0.77
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia. Oncologist (2010) 0.77
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J (2015) 0.75
Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans. AAPS J (2015) 0.75
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. J Clin Pharmacol (2016) 0.75
Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure. J Clin Pharmacol (2015) 0.75
Toward evidence-based medical statistics. 2: The Bayes factor. Ann Intern Med (1999) 5.78
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J (2002) 2.77
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol (2006) 2.69
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res (2001) 2.64
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest (1998) 2.62
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol (2002) 2.44
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics (2007) 2.01
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res (2000) 1.85
Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res (2002) 1.78
Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol (2002) 1.57
Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res (1996) 1.55
Chemotherapy of advanced gastric cancer. Cancer Treat Rev (2007) 1.50
Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos (2004) 1.45
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res (2001) 1.17
Insights, challenges, and future directions in irinogenetics. Ther Drug Monit (2007) 1.17
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res (2000) 1.17
Lessons learned from the irinotecan metabolic pathway. Curr Med Chem (2003) 1.08
Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics (2005) 1.08
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics (2002) 1.03
Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun (1999) 0.98
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther (2002) 0.91
Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol (2005) 0.90
Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol (1998) 0.89
Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos (2002) 0.88
Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkey. Eur J Pharm Sci (2005) 0.88
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther (2004) 0.86
Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers. Ther Drug Monit (1993) 0.85
Second- and third-line treatments in non-small cell lung cancer. Curr Treat Options Oncol (2006) 0.84
New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. Oncologist (2007) 0.83
Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biol Ther (2006) 0.80
Second-line treatment of small-cell lung cancer. Curr Oncol Rep (2006) 0.79
Effect modelling for drugs undergoing enterohepatic circulation. Eur J Drug Metab Pharmacokinet (1994) 0.79
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol (1995) 5.86
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther (2012) 3.15
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J (2002) 2.77
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol (1998) 2.69
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest (1998) 2.62
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther (1999) 1.94
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res (2000) 1.93
Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther (2007) 1.90
Oral chemotherapy: rationale and future directions. J Clin Oncol (1998) 1.88
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res (1994) 1.72
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
Modeling immunotherapy of the tumor-immune interaction. J Math Biol (1998) 1.62
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB (2001) 1.62
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol (2000) 1.56
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther (2012) 1.55
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest (1999) 1.47
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood (1990) 1.44
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst (1994) 1.44
Anticancer drug discovery and development throughout the world. J Clin Oncol (2002) 1.42
Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs (2001) 1.35
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol (1992) 1.24
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol (1998) 1.23
Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos (2001) 1.21
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol (1997) 1.20
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol (1998) 1.16
Outcome of the use of pediatric donor livers in adult recipients. Liver Transpl (2001) 1.14
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol (2003) 1.11
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia (2012) 1.10
Molecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer. Breast Cancer Res (2000) 1.09
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res (2000) 1.09
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol (1997) 1.07
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst (1997) 1.07
Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J (2011) 1.05
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol (1997) 1.03
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol (2005) 1.02
Biomarkers in early cancer drug development: limited utility. Clin Pharmacol Ther (2009) 1.01
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst (1993) 1.00
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther (1989) 0.98
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res (2000) 0.98
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol (2006) 0.98
Prognostic factors for survival in patients treated in phase I clinical trials. Cancer (1994) 0.98
Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J (2007) 0.97
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res (2001) 0.97
Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. Eur J Neurol (2007) 0.97
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol (2003) 0.96
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J (2012) 0.95
Pharmacogenetics in cancer treatment. Annu Rev Med (2001) 0.95
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos (2001) 0.95
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol (1998) 0.95
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer (1989) 0.94
Treatment of hairy cell leukemia with recombinant alpha 2 interferon. Blood (1985) 0.94
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol (1996) 0.94
Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin Cancer Res (1995) 0.94
Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst (1992) 0.93
Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension. Am J Hypertens (1989) 0.93
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood (1992) 0.93
Pharmacogenetics and cancer chemotherapy. Eur J Cancer (1998) 0.92
Cancer chemotherapy and skin changes. Ann Intern Med (1985) 0.92
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Cancer Res (1994) 0.92
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J (2008) 0.91
A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. Math Biosci (2001) 0.91
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst (1990) 0.91
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol (1998) 0.91
Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol (1998) 0.91
Skeletal complications in hairy cell leukemia: diagnosis and therapy. J Clin Oncol (1988) 0.90
Pushing the envelope: informed consent in phase I trials. Ann Oncol (1995) 0.90
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol (1991) 0.90
Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Pharmacogenomics J (2012) 0.89
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol (1993) 0.89
Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol (1998) 0.89
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. Eur J Clin Pharmacol (2002) 0.89
Transthoracic three-dimensional echocardiographic reconstruction of left and right ventricles: in vitro validation and comparison with magnetic resonance imaging. Am Heart J (1997) 0.88
Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice. J Hum Hypertens (2009) 0.88
Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med (1997) 0.88
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther (2009) 0.87
Limited sampling model for area under the concentration time curve of total topotecan. Clin Cancer Res (1996) 0.87
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res (1998) 0.86
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer (1997) 0.86
Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol (1999) 0.86
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol (1998) 0.86
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther (2007) 0.85
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol (2004) 0.85
Individualizing dosing of cancer chemotherapy. Semin Oncol (1993) 0.84
First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. Br J Cancer (2008) 0.84
A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther (1995) 0.83
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). Ann Oncol (2001) 0.83
First measurements of a carbon dioxide plume from an industrial source using a ground based mobile differential absorption lidar. Environ Sci Process Impacts (2014) 0.83
The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys (2001) 0.83
Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. Br J Cancer (2000) 0.83
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res (1999) 0.83
Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther (1987) 0.82
A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer (1994) 0.82
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res (1995) 0.82
A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res (1989) 0.82
Cardiac and vascular remodeling in older adults with borderline isolated systolic hypertension: the ICARe Dicomano Study. Hypertension (2001) 0.82
Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. Clin Exp Rheumatol (1998) 0.82